These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 34680766)
1. Antibacterial Activity of LCB10-0200 against Oh SH; Kim YR; Park HS; Oh KM; Cho YL; Kwak JH Antibiotics (Basel); 2021 Sep; 10(10):. PubMed ID: 34680766 [No Abstract] [Full Text] [Related]
2. Antimicrobial activities of LCB10-0200, a novel siderophore cephalosporin, against the clinical isolates of Pseudomonas aeruginosa and other pathogens. Oh SH; Park HS; Kim HS; Yun JY; Oh K; Cho YL; Kwak JH Int J Antimicrob Agents; 2017 Dec; 50(6):700-706. PubMed ID: 28668680 [TBL] [Abstract][Full Text] [Related]
3. In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant Nguyen LP; Park CS; Pinto NA; Lee H; Seo HS; Vu TN; Mai H; Pham AHT; Jang E; Cho YL; Goglin K; Nguyen K; White R; D'Souza R; Fouts DE; Yong D Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33923801 [TBL] [Abstract][Full Text] [Related]
4. In Vitro Activity of a Novel Siderophore-Cephalosporin, GT-1 and Serine-Type β-Lactamase Inhibitor, GT-055, against Nguyen LP; Pinto NA; Vu TN; Lee H; Cho YL; Byun JH; D'Souza R; Yong D Antibiotics (Basel); 2020 May; 9(5):. PubMed ID: 32443875 [TBL] [Abstract][Full Text] [Related]
5. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
7. Antimicrobial polymers as therapeutics for treatment of multidrug-resistant Klebsiella pneumoniae lung infection. Lou W; Venkataraman S; Zhong G; Ding B; Tan JPK; Xu L; Fan W; Yang YY Acta Biomater; 2018 Sep; 78():78-88. PubMed ID: 30031912 [TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Aktaş Z; Kayacan C; Oncul O Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508 [TBL] [Abstract][Full Text] [Related]
10. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017). Rossolini GM; Stone GG Int J Antimicrob Agents; 2020 Sep; 56(3):106111. PubMed ID: 32721602 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of antibacterial effects of Zataria multiflora Boiss extracts against ESBL-producing Klebsiella pneumoniae strains. Dadashi M; Hashemi A; Eslami G; Fallah F; Goudarzi H; Erfanimanesh S; Taherpour A Avicenna J Phytomed; 2016; 6(3):336-43. PubMed ID: 27462557 [TBL] [Abstract][Full Text] [Related]
12. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Sharma R; Park TE; Moy S Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model. Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129 [TBL] [Abstract][Full Text] [Related]
14. Degradable antimicrobial polycarbonates with unexpected activity and selectivity for treating multidrug-resistant Klebsiella pneumoniae lung infection in mice. Yang C; Lou W; Zhong G; Lee A; Leong J; Chin W; Ding B; Bao C; Tan JPK; Pu Q; Gao S; Xu L; Hsu LY; Wu M; Hedrick JL; Fan W; Yang YY Acta Biomater; 2019 Aug; 94():268-280. PubMed ID: 31129359 [TBL] [Abstract][Full Text] [Related]
15. Phenotypic and Molecular Characterization of Extended-Spectrum β-Lactamase Produced by Escherichia coli, and Klebsiella pneumoniae Isolates in an Educational Hospital. Gholipour A; Soleimani N; Shokri D; Mobasherizadeh S; Kardi M; Baradaran A Jundishapur J Microbiol; 2014 Oct; 7(10):e11758. PubMed ID: 25632322 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015. Sader HS; Castanheira M; Flamm RK Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of two multidrug-resistant Klebsiella species in an Indian teaching hospital and adjoining community. Rath S; Padhy RN J Infect Public Health; 2014; 7(6):496-507. PubMed ID: 24996691 [TBL] [Abstract][Full Text] [Related]
20. Cure of recurring Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae septic shock episodes due to complicated soft tissue infection using a ceftazidime and avibactam-based regimen: a case report. Parruti G; Frattari A; Polilli E; Savini V; Sciacca A; Consorte A; Cibelli DC; Agostinone A; Di Masi F; Pieri A; Cacciatore P; Di Iorio G; Fazii P; Spina T J Med Case Rep; 2019 Jan; 13(1):20. PubMed ID: 30665450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]